The biology underlying the approval is rooted in one of the most consequential discoveries in modern cancer genetics. DNA mismatch repair is a cellular quality-control system responsible for correcting errors that arise when DNA is copied during cell division. When the genes encoding this machinery, most commonly MLH1, MSH2, MSH6, or PMS2, are defective or silenced, errors accumulate in stretches of repetitive DNA known as microsatellites, producing a state called microsatellite instability. The resulting tumors carry an exceptionally high burden of mutations, and those mutations are translated into abnormal protein fragments that the immune system can recognize as foreign. This neoantigen-rich environment explains why dMMR tumors respond unusually well to immune checkpoint inhibitors, drugs that release the molecular brakes, such as the PD-L1/PD-1 axis targeted by atezolizumab, that cancers use to evade immune destruction. Paradoxically, however, dMMR tumors are less sensitive to fluoropyrimidine-based chemotherapy, the historical backbone of adjuvant treatment, leaving a critical therapeutic gap that the ATOMIC trial was designed to close.

Colorectal cancer remains the second leading cause of cancer-related death worldwide, and stage III disease, in which cancer has spread to nearby lymph nodes but not to distant organs, represents a pivotal and potentially curable stage. For decades, the standard adjuvant treatment for all patients with stage III colon cancer, regardless of molecular subtype, has been chemotherapy with a fluoropyrimidine combined with oxaliplatin, typically delivered as the FOLFOX regimen. Yet even with this treatment, a substantial proportion of patients experience recurrence, and the diminished sensitivity of dMMR tumors to fluoropyrimidines meant that this subgroup derived comparatively limited benefit from the existing standard. That unmet need provided a strong scientific rationale for a biomarker-driven approach, one that would match the distinctive immunogenicity of dMMR tumors with an agent capable of exploiting it, rather than treating all stage III colon cancers as a single, uniform disease.

The ATOMIC trial enrolled 712 participants between September 2017 and January 2023 across the United States and in Germany, a scale of accrual that investigators attribute to the infrastructure of the National Cancer Institute’s National Clinical Trials Network. Patients with stage III colon cancer and confirmed mismatch repair deficiency were randomized to receive either standard adjuvant chemotherapy alone or chemotherapy combined with atezolizumab. The trial was designed with disease-free survival as its primary endpoint, while overall survival and safety were designated as secondary endpoints, a structure that enabled a comprehensive assessment of both the efficacy and the tolerability of integrating immunotherapy into the adjuvant setting, where patients have already been rendered surgically disease-free and treatment is intended to prevent relapse rather than shrink measurable tumors.

The results, recently published in The New England Journal of Medicine, were striking. Adding atezolizumab to standard adjuvant chemotherapy reduced the risk of cancer recurrence or death by fifty percent, a magnitude of benefit rarely achieved in the adjuvant treatment of gastrointestinal malignancies. After three years of follow-up, 86.3 percent of patients who received the combination remained disease-free, compared with 76.2 percent of those who received chemotherapy alone. In practical terms, the immunotherapy combination translated into roughly one additional patient in ten remaining free of cancer three years after surgery, an absolute improvement with profound implications for a disease in which recurrence after stage III diagnosis frequently presages incurable metastatic spread. The ten-percentage-point separation between the curves, sustained over years, provided the evidentiary foundation on which the regulatory decision was built.

Leadership of the Alliance for Clinical Trials in Oncology framed the approval as both a clinical and an institutional milestone. Evanthia Galanis, MD, DSc, Group Chair of the Alliance, said that the approval of atezolizumab for patients with stage III dMMR colon cancer is a significant milestone for patients and for the organization, noting that the ATOMIC trial demonstrates the potential of introducing immunotherapy earlier in the course of cancer treatment, when the disease is still potentially curable, with the goal of preventing recurrence and increasing the number of patients who can be cured. She added that the trial also demonstrates the power of the National Cancer Institute’s National Clinical Trials Network to conduct large, definitive trials that answer important questions in cancer management and translate those findings into a new standard of care, and that the results show what is possible when investigators across the country come together around a common goal.

Frank A. Sinicrope, MD, the Alliance Study Chair for ATOMIC and a Professor of Oncology and Clinical Investigator of the Mayo Foundation at the Mayo Clinic Comprehensive Cancer Center, emphasized the clinical and scientific significance of the findings. He said the results provide compelling evidence that immunotherapy can play an important role in reducing the risk of recurrence and death after surgery for patients with stage III dMMR colon cancer, and that the FDA approval is an important step in bringing the benefits demonstrated in the trial into routine clinical practice. He also underscored a broader principle that is increasingly shaping oncology: the approval reinforces the importance of understanding the molecular characteristics of a patient’s tumor and using that information to guide treatment. He expressed gratitude to the patients and investigators who made the study possible and helped establish the new treatment regimen.

The trial’s execution reflected a public-private partnership model that has become central to modern cancer drug development. ATOMIC was sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the Alliance within the NCI-funded National Clinical Trials Network. Genentech provided support to the study through a Cooperative Research and Development Agreement with the NCI, an arrangement that allowed an academic-public consortium to evaluate a commercial immunotherapy agent in a biomarker-defined population while retaining the scientific independence and broad accrual capacity characteristic of network trials. The Alliance itself unites more than 26,000 cancer specialists at 112 main institutions and nearly 1,500 affiliates across the United States and Canada, and also serves as a leading research base for the NCI Community Oncology Research Program, enabling practice-changing trials to reach patients in both academic centers and community settings.

The broader implications extend well beyond a single drug approval. ATOMIC adds to a growing body of evidence that mismatch repair deficiency is one of the most predictive biomarkers in oncology, a molecular signature that reliably identifies patients likely to benefit from checkpoint blockade across disease stages and tumor types. By moving immunotherapy from the metastatic and locally advanced settings into the adjuvant treatment of early-stage colon cancer, the trial demonstrates that immune checkpoint inhibition can prevent recurrence, not merely control established disease, and that earlier intervention may increase the number of patients who are ultimately cured. The approval also validates the strategy of biomarker-driven trial design, in which a molecularly defined subgroup is studied prospectively rather than discovered retrospectively, and it reinforces the value of disease-free survival as an endpoint capable of supporting regulatory decisions when the biological link to overall survival is well established.

For patients, the practical consequence is a new standard of care: those diagnosed with stage III colon cancer will now undergo molecular testing for mismatch repair status as a routine part of treatment planning, and those whose tumors are dMMR will be eligible to receive atezolizumab alongside fluoropyrimidine and oxaliplatin chemotherapy after surgery. The full description of the clinical trial is available through ClinicalTrials.gov under identifier NCT02912559, and the primary results were published by Sinicrope and colleagues in The New England Journal of Medicine in March 2026. As immunotherapy continues its migration earlier into the treatment course of cancers with recognizable immune vulnerabilities, the ATOMIC trial and the approval it produced stand as a template for how large cooperative-group studies, molecular diagnostics, and public-private collaboration can converge to convert fundamental insights about tumor immunology into tangible gains in survival.

Subject of Research: Adjuvant immunotherapy with atezolizumab for stage III deficient DNA mismatch repair colon cancer based on the phase III ATOMIC trial

Article Title: Alliance announces FDA approval of atezolizumab based on results from the Phase III ATOMIC trial for patients with Stage III dMMR colon cancer

Article References: Alliance announces FDA approval of atezolizumab based on results from the Phase III ATOMIC trial for patients with Stage III dMMR colon cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: atezolizumab, colon cancer, dMMR, microsatellite instability, immunotherapy, ATOMIC trial, adjuvant chemotherapy, FDA approval, clinical trial, Alliance for Clinical Trials in Oncology, National Cancer Institute, disease-free survival

The trial, known as FAB-HCC, enrolled twelve patients with advanced hepatocellular carcinoma who had progressed while receiving atezolizumab plus bevacizumab. The rationale rested on a growing body of evidence that the gut microbiome can act as a rheostat for the immune system, shaping how effectively checkpoint inhibitors unleash T cells against tumors. In cancers such as melanoma, earlier studies had shown that transferring fecal material from patients who responded to immunotherapy into those who did not could sometimes rekindle the anti-tumor response. The Vienna team extended this concept in two directions: they tested the approach in liver cancer, a tumor type arising in an organ intimately connected to the gut through the portal circulation, and they compared donors of two kinds, a patient with hepatocellular carcinoma who had responded robustly to anti-PD-1 therapy and a healthy individual.

Each participant received a single fecal microbiota transplantation via colonoscopy, followed by continued treatment with atezolizumab and bevacizumab. The primary endpoint of the study was safety, measured by the incidence and severity of treatment-related adverse events. This was a critical question, because both fecal transplants and the drug combination carry theoretical risks, particularly in patients with cirrhotic livers whose immune function is already compromised. The results were reassuring. The most frequent grade 3 or 4 treatment-related adverse events were arterial hypertension, seen in five patients, and proteinuria, seen in three, both of which are well-known toxicities of bevacizumab rather than consequences of the transplant. A single case of grade 3 diarrhea was attributed to the fecal microbiota transplantation itself. Importantly, no serious treatment-related adverse events were observed, and the procedure proved feasible in this vulnerable population.

The efficacy signals, while generated in a very small cohort, were eye-catching. Four of the twelve patients, an objective response rate of 33 percent, experienced radiologically confirmed tumor shrinkage after their disease had stopped responding to the same drug combination. The median progression-free survival was 6.9 months, with a 95 percent confidence interval spanning 3.0 to 10.8 months. For a population in which rechallenge with the same regimen would ordinarily be expected to yield little benefit, these numbers suggest that modulating the gut ecosystem may genuinely change the biological terrain on which immunotherapy operates. The authors are careful to frame the trial as hypothesis-generating, and with twelve participants, chance and selection effects cannot be excluded. Still, the consistency between the clinical outcomes and the molecular findings lends the results biological plausibility.

That plausibility comes from an unusually deep set of translational analyses. By sequencing microbial DNA from stool samples collected before and after the transplant, the researchers tracked whether the donor’s microbial community took up residence in the recipient, a phenomenon known as engraftment. After the procedure, the composition of the recipients’ gut microbiomes shifted toward that of their respective donors, indicating that a single colonoscopic delivery can durably alter the intestinal ecosystem. Notably, transplants from the healthy donor appeared to engraft more successfully than those from the responding patient, an observation with practical implications for how donor material might be selected in future trials. The team also documented a meaningful ecological shift in function: bacteria previously associated with immunotherapy response became enriched after the transplant, while deleterious species waned.

The immune consequences of this microbial remodeling were visible in the blood. Following the combined intervention, the number of circulating PD-1-positive CD8-positive T cells, a population often expanded in settings of chronic antigen stimulation and immune exhaustion, decreased. At the same time, a specific subset of monocytes, characterized by the marker CD32b and high expression of CD14 with low CD16, increased. Monocytes and their derivatives are increasingly recognized as key orchestrators of the tumor microenvironment, capable of either supporting or suppressing T-cell activity, and shifts in these populations may reflect a rebalancing of innate immunity toward a more inflammation-competent state. These cellular changes provide a mechanistic bridge between the microbial intervention and the clinical responses observed on imaging.

Perhaps the most novel analytical contribution came from an antibody-sequencing approach known as phage-display immunoprecipitation sequencing, which profiles the repertoire of antibodies circulating in a patient’s blood by measuring their binding to hundreds of thousands of synthetic peptide displays. Rather than finding that overall antibody diversity or composition predicted outcome, the researchers discovered that the stability of the antibody repertoire over time was what changed following the intervention. This suggests that the humoral immune system, the arm responsible for antibody production, undergoes a measurable recalibration when the gut ecosystem is reset and checkpoint blockade is resumed. It is a reminder that cancer immunotherapy responses are systemic events, rippling far beyond the tumor itself, and that tools capable of reading these ripples may eventually help identify which patients are responding long before scans can.

The study also carries a poignant human dimension. The responding patient who served as one of the donors represents a rare example of a cancer patient directly contributing biological material that may benefit others with the same disease. The trial was conducted at a single center with support from Roche, which supplied the investigational medicinal product, and it was registered under ClinicalTrials.gov identifier NCT05750030. The authors acknowledge with gratitude the contributions of patients, donors, and their families, as well as a statistician who contributed to the trial’s design and passed away before its completion, a quiet reminder of the human effort underlying every clinical dataset.

What happens next will determine whether this approach moves from promising pilot to standard of care. The central limitation is unmistakable: twelve patients, no control group, and an open-label design in which neither patients nor physicians were blinded to the intervention. Spontaneous fluctuations in hepatocellular carcinoma, and the possibility that simply continuing atezolizumab and bevacizumab after a treatment holiday benefits some patients, cannot be ruled out. Larger, adequately powered, ideally randomized trials will be needed to confirm that fecal microbiota transplantation genuinely reverses resistance rather than merely coinciding with it. If those trials succeed, the implications would extend well beyond liver cancer. The gut microbiome is already implicated in responses to checkpoint inhibitors across melanoma, lung cancer, and renal cell carcinoma, and a safe, single-procedure intervention that reprograms it could become a universal sensitizing strategy. For now, the Vienna results offer something oncology rarely enjoys after a treatment fails: a scientifically grounded reason to try again, delivered not with a new molecule but with the microscopic residents of a healthier gut.

Subject of Research: Fecal microbiota transplantation combined with atezolizumab-bevacizumab rechallenge in immunotherapy-refractory hepatocellular carcinoma

Article Title: FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study

Article References: Pomej, K., Frick, A., Scheiner, B., Baumgartner, M., Schmetterer, K. G., Reyna-Blanco, C. S., Balcar, L., Pajancic, L., Kreuter, A., Séneca, J., Hausmann, B., Köcher, T., Prinzensteiner, M., Lampichler, K., Rohr-Udilova, N., Chakrabarty, A., Klotz, A., Lampl, A. C., Zinober, K., … Pinter, M. (2026). FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study. Nature Communications. https://doi.org/10.1038/s41467-026-78219-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78219-z

Keywords: fecal microbiota transplantation, hepatocellular carcinoma, atezolizumab, bevacizumab, immunotherapy resistance, gut microbiome, checkpoint inhibitors, phase II pilot study, microbiome engraftment, PD-1, tumor immunology, Nature Communications

The story began in February 2022, when the patient was admitted to a hospital with hoarseness and coughing up blood. Imaging and pathology confirmed left lung adenocarcinoma with brain metastases, classified as stage IV under the American Joint Committee on Cancer TNM staging system, eighth edition. His tumor biology was aggressive: immunohistochemistry revealed a Ki-67 proliferation index of 70 percent and a PD-L1 tumor proportion score of 90 percent, while genetic testing showed wild-type EGFR and ALK. Because his tumor expressed PD-L1 so strongly, he was enrolled in a randomized, double-blind, placebo-controlled trial testing an anti-TIGIT antibody alongside atezolizumab for advanced non-small cell lung cancer. On March 21, 2022, he completed one cycle of atezolizumab at 1,200 milligrams plus the anti-TIGIT antibody or placebo at 600 milligrams, both intravenously, without immediate complications.

Less than a month later, the trouble started. The patient developed fatigue, facial swelling, and a rash. Laboratory tests on April 18, 2022 revealed elevated liver enzymes, with alanine aminotransferase at 71.9 units per liter and aspartate aminotransferase at 193.1 units per liter, along with abnormal cardiac markers including cardiac troponin T at 0.036 nanograms per milliliter, creatine kinase-MB at 41.8, and myoglobin at 1,371 nanograms per milliliter. Doctors at the first hospital suspected immune-related myocarditis, hepatitis, and secondary adrenal insufficiency, stopped the immunotherapy, and started methylprednisolone at 60 milligrams twice daily, later escalating the dose. Follow-up was disrupted by the COVID-19 pandemic, and by late May the patient had worsening chest discomfort, severe facial and neck edema, and a widespread rash. Neck computed tomography showed tonsillitis and inflammation of the parotid and submandibular glands compressing the trachea enough to require intubation. His platelet count then crashed to 15 times 10 to the ninth per liter, and his liver function deteriorated further.

When the patient reached the team at Zhongshan Hospital, Fudan University, the physicians conducted a systematic re-evaluation of each suspected immune-related adverse event. Cardiac magnetic resonance imaging with enhancement revealed scattered patchy enhancement in the left ventricular lateral wall and linear delayed enhancement in the subepicardium of the inferoposterior wall, findings strongly suggestive of grade 3 checkpoint inhibitor myocarditis, with a left ventricular ejection fraction of 50 percent. Pulmonary embolism and worsening of pre-existing cardiovascular disease were ruled out. A liver biopsy showed mild sinusoidal congestion, subtle inflammatory infiltration, bile stasis, hepatocyte swelling, and focal necrosis, consistent with grade 2 immune-related hepatic injury in the absence of liver metastases, viral hepatitis, or autoimmune disease. A bone marrow biopsy demonstrated poor maturation of megakaryocytes without tumor invasion, supporting grade 4 immune-mediated thrombocytopenia. Finally, the combination of widespread muscle soreness, facial and periorbital swelling, elevated creatine kinase dominated by the skeletal muscle fraction, and impaired self-care pointed to grade 4 dermatomyositis, with the MDA5 antibody testing negative.

Treatment was aggressive and multidisciplinary. The patient received intravenous methylprednisolone at 160 milligrams daily for five days, together with intravenous immunoglobulin at 20 grams daily for seven days, plus hepatoprotective, gastric-protective, anti-infective, and nutritional support. Cardiac troponin stabilized and platelet counts rose significantly, but liver enzymes and bilirubin continued climbing, prompting the addition of tofacitinib, a Janus kinase inhibitor, at 5 milligrams per day starting June 11, 2022. Liver function and the rash gradually improved, allowing tapering of the methylprednisolone from June 19 onward. After discharge, steroids were tapered weekly, and tofacitinib was stopped when the oral dose reached 30 milligrams per day. Yet each attempt to withdraw immunosuppression backfired: at 10 milligrams of methylprednisolone, pruritic rashes reappeared on the right lower limb with rising creatine kinase-MB, requiring a five-day course of intravenous methylprednisolone at 40 milligrams. A second taper attempt triggered worsening rashes and elevations in troponin, creatine kinase, and creatine kinase-MB, and tofacitinib was reintroduced.

Because the dermatomyositis persisted and multiple organ systems remained involved, steroid withdrawal proved impossible. The team settled on a long-term maintenance regimen of low-dose methylprednisolone, 5 milligrams every other day, plus tofacitinib 5 milligrams twice daily. To date, the patient has improved markedly, with rashes substantially alleviated, normal liver function, and normalization of most cytokines and cardiac markers. In a striking twist, he has received no anti-tumor therapy since the adverse events began, yet his tumor remained stable for a long period, a phenomenon the authors note with interest, before follow-up chest computed tomography on December 13, 2024 showed localized recurrence.

The clinical course illustrates why checkpoint inhibitor myocarditis demands such vigilance. Although cardiac involvement is among the rarer immune-related adverse events, it carries a mortality rate of 25 to 50 percent, with rapid onset, atypical symptoms, and swift progression. Risk factors include combination checkpoint blockade, concurrent cardiotoxic cancer drugs, and pre-existing cardiovascular disease. High-dose corticosteroids are the cornerstone of treatment, and guidelines such as those from the National Comprehensive Cancer Network recommend permanent discontinuation of checkpoint inhibitors, electrocardiographic and echocardiographic monitoring, and pulsed methylprednisolone for three to five days in grade 3 cases, followed by tapering over four to six weeks. When patients resist steroid pulse therapy, guidelines suggest adding a chemotherapeutic or biological agent plus immunoglobulins, with antithymocyte globulin or alemtuzumab offering potential advantages. In this case, the combination of immunoglobulin and tofacitinib alongside steroids appeared to play a critical role in achieving disease control.

The hepatic and hematological complications add further lessons. Immune-related liver injury typically emerges six to fourteen weeks after starting checkpoint inhibitors, with an incidence around 8.4 percent in one cited cohort, and patients receiving dual immune therapy are more susceptible to hepatotoxicity. Steroid dosing for hepatitis is generally lower than for myocarditis, scaled to the grade of liver dysfunction, and the pathological basis, autoimmune cells attacking normal hepatocytes, mirrors that of cardiac injury. The authors also raise an unresolved question: when patients are already on high-dose steroids and immunoglobulins, should standard hepatoprotective drugs be continued? Current guidelines offer little guidance on this point. Immune thrombocytopenia, meanwhile, occurs in fewer than 1 percent of checkpoint inhibitor recipients, usually within the first twelve weeks, and remains a diagnosis of exclusion. Because thrombocytopenia is common in cancer patients, clinicians must systematically rule out infection, tumor progression, and drug effects before attributing it to immunotherapy, as the team did here through bone marrow biopsy and careful history-taking.

What makes this case scientifically valuable is its rarity and its implications for the next generation of immunotherapy. TIGIT, a co-inhibitory receptor expressed on T cells and natural killer cells that competes with the costimulatory molecule CD226 for the ligands CD155 and CD112, has shown synergistic anti-tumor effects with PD-1 and PD-L1 blockade in preclinical studies, and trials of tiragolumab combinations have generally reported acceptable safety profiles. Yet this patient experienced four simultaneous, severe immune-related adverse events after a single treatment cycle, underscoring that combining checkpoints acting on different pathways can amplify loss of immune tolerance in unpredictable ways. The authors emphasize that multisystemic immune-related adverse events tend to appear early and progress rapidly, that glucocorticoids remain the core therapy, and that severe cases may require intravenous immunoglobulin, plasma exchange, or additional immunomodulatory drugs such as tofacitinib. For oncologists deploying anti-TIGIT and anti-PD-L1 combinations in trials and clinics, the message is clear: early recognition, precise diagnosis across organ systems, and prompt multidisciplinary intervention can mean the difference between catastrophe and recovery.

Subject of Research: Multisystemic immune-related adverse events from anti-PD-L1 and anti-TIGIT combination immunotherapy in lung adenocarcinoma

Article Title: Management of multisystemic irAEs associated with atezolizumab/tiragolumab combination therapy in a patient with lung adenocarcinoma: case report and review

Article References: Zhang, S., Zhang, N., Lin, J., Zhao, L., Jin, H., Gao, D., Ji, Z., Liu, Q., Ai, L., & Yu, Y. (2025). Management of multisystemic irAEs associated with atezolizumab/tiragolumab combination therapy in a patient with lung adenocarcinoma: case report and review. Clinical Cancer Bulletin, 4(1), Article 6. https://doi.org/10.1007/s44272-025-00034-2

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00034-2

Keywords: immune checkpoint inhibitors, atezolizumab, tiragolumab, TIGIT, PD-L1, myocarditis, immune-related adverse events, lung adenocarcinoma, dermatomyositis, thrombocytopenia, hepatitis, tofacitinib

The trial enrolled thirty patients with relapsed or refractory small cell lung cancer who had already progressed after platinum-based chemotherapy, a population where effective options are scarce and median survival is typically measured in months. The treatment sequence was deliberately simple. Each patient received 24 Gy of hypofractionated radiotherapy delivered in four fractions every other day, a schedule designed to deposit substantial radiation dose in a compressed timeframe. Immediately afterward, patients began atezolizumab at 1200 mg every three weeks. The rationale rested on a growing body of preclinical and clinical evidence suggesting that radiation can do more than kill tumor cells directly. Hypofractionated doses can trigger immunogenic cell death, releasing tumor antigens and danger signals that recruit and activate immune cells, potentially converting an irradiated tumor into something resembling an in situ vaccine that checkpoint blockade can then amplify.

The clinical outcomes told a sobering story about the difficulty of treating this disease in an unselected population. The objective response rate was 80.0 percent for the radiotherapy component itself, confirming that the tumors were radiosensitive, as small cell lung cancer characteristically is. But when atezolizumab took over as the systemic agent, the response rate fell to just 16.7 percent. Median progression-free survival was 2.5 months, with only 6.9 percent of patients remaining progression-free at six months. Median overall survival reached 10.4 months, and 41.8 percent of patients were alive at one year, figures that are respectable for relapsed disease but fall short of a breakthrough. The gap between local radiosensitivity and systemic immunotherapy benefit is precisely the puzzle the trial’s exploratory immune profiling was designed to address.

That profiling began with serial blood draws. Peripheral blood mononuclear cells were collected before radiotherapy and again after its completion, then analyzed using multiparametric flow cytometry, a technique that tags cells with fluorescent antibodies and sorts them by the proteins they display on their surfaces. The investigators focused on two cell types with very different immunological roles. The first was the natural killer T cell, identified as cells carrying both CD3, a pan-T-cell marker, and CD56, a marker shared with natural killer cells. NKT cells sit at the interface of innate and adaptive immunity, capable of rapid cytokine release and of bridging radiation-induced inflammation to broader antitumor responses. The second was the classical monocyte, defined as CD14-high and CD16-negative, with particular attention to the fraction of these cells expressing programmed death-ligand 1, the same molecule that atezolizumab blocks.

The NKT cell findings were the trial’s first revelation. Patients whose disease remained controlled for three months or longer on progression-free survival started with significantly lower circulating NKT cell frequencies at baseline than patients who progressed sooner, a difference that reached statistical significance at p equals 0.02. More striking still was what happened after radiation. In the longer-survival group, NKT cell numbers expanded after radiotherapy, with a median fold-change of 1.3, while in the shorter-survival group they contracted, with a fold-change of 0.9. The difference between these trajectories was statistically significant at p equals 0.011. In other words, the direction of change, not simply the starting point, carried prognostic information. A radiation-induced surge in these innate-like lymphocytes in the bloodstream appeared to mark patients whose immune systems could be mobilized into a durable antitumor posture.

The monocyte data told a complementary story. Classical monocytes are the most abundant monocyte subset in human blood, and when they express PD-L1, they are often interpreted as soldiers of an immunosuppressive program, cells that dampen T-cell activity and can be recruited by tumors as shields against immune attack. Yet in this trial, a post-radiotherapy increase in PD-L1-expressing classical monocytes was associated with benefit. Patients with progression-free survival of three months or longer showed a median fold-increase of 2.8 in these cells after radiation, compared with only 0.7 in the shorter-survival group, a difference significant at p equals 0.0085. One plausible interpretation is that radiation drove a wave of inflammatory monocyte mobilization, and the PD-L1 expression on those cells represented a druggable vulnerability rather than an insurmountable barrier, a target that atezolizumab could engage precisely because the cells were present and ligand-loaded.

Read together, the two signatures suggest that radiotherapy does not simply damage tumors; it measurably reprograms the innate immune compartment in the periphery, and the pattern of that reprogramming predicts who will benefit from subsequent checkpoint blockade. This is a conceptually important shift. Most biomarker research in immunotherapy has concentrated on the tumor itself, examining PD-L1 staining on biopsy specimens, tumor mutational burden, or the density of lymphocyte infiltration. Small cell lung cancer frustrates these approaches because biopsies are difficult to obtain in relapsed patients and the tumor microenvironment is often profoundly immunosuppressed. A blood test that requires only serial peripheral blood draws, analyzed by standard flow cytometry, would be far more practical for a patient population that is often too fragile for repeat invasive procedures.

The trial’s limitations deserve honest framing. Thirty patients is a small cohort, the study was single-arm without a randomized control receiving atezolizumab alone, and the immune correlates were pre-specified as exploratory rather than confirmatory objectives. Correlates identified in a phase II setting must be validated in larger, ideally randomized, cohorts before they can guide clinical decisions. There is also a biological ambiguity to resolve: whether the NKT cell expansion and monocyte PD-L1 induction are causal drivers of benefit, passive readouts of a favorable radiation response, or both. Answering that question will require mechanistic studies that connect the peripheral blood observations to what is happening inside the irradiated tumor and in distant metastatic sites.

Even so, the study adds a meaningful piece to one of the most active puzzles in modern oncology: how to make radiation and immunotherapy work as true partners rather than sequential monotherapies. The abscopal effect, in which localized radiation shrinks tumors far from the treatment field, has tantalized researchers for decades but remains rare in practice, likely because it depends on a permissive immune context that most patients’ tumors and immune systems do not spontaneously provide. Biomarkers like the ones identified here, dynamic and measured in blood, could eventually allow clinicians to identify which patients carry that permissive biology before committing them to combination therapy, and to test interventions, such as altered radiation fractionation or additional immune modulators, in those who do not. For a disease as aggressive and under-served as relapsed small cell lung cancer, even a modest systemic signal paired with a usable predictive signature represents progress worth building on, and the Korean team’s finding that innate immune reprogramming can be tracked in a simple blood sample may prove to be the trial’s most enduring legacy.

Subject of Research: Immune correlates of radiotherapy-primed atezolizumab in relapsed small cell lung cancer

Article Title: Dynamics of peripheral blood NKT cells and PD-L1-expressing classical monocytes as immune correlates of radiotherapy-primed atezolizumab in relapsed small cell lung cancer: a phase II study

Article References: Suh, Y.-G., Lee, Y., Moon, S. H., Lee, S., & Han, J.-Y. (2026). Dynamics of peripheral blood NKT cells and PD-L1-expressing classical monocytes as immune correlates of radiotherapy-primed atezolizumab in relapsed small cell lung cancer: a phase II study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04570-1

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04570-1

Keywords: small cell lung cancer, atezolizumab, hypofractionated radiotherapy, NKT cells, classical monocytes, PD-L1, immune checkpoint inhibitor, immune biomarkers, phase II trial, radio-immunotherapy, flow cytometry, progression-free survival

The central problem the researchers set out to address is the immunosuppressive tumor microenvironment that characterizes hepatocellular carcinoma. Like many solid tumors, liver cancers do not simply grow in isolation; they actively construct a hostile landscape around themselves, deploying molecular signals and surface proteins that suppress or evade the immune cells that would otherwise eliminate them. Standard immunotherapies, including the combination of atezolizumab, an antibody that blocks the PD-L1 checkpoint pathway, and bevacizumab, an antibody that starves tumors by inhibiting the VEGF signaling that drives blood vessel formation, have improved outcomes for many patients. Yet resistance remains common, and the field has been searching for strategies that can convert immunologically cold, treatment-resistant tumors into ones the immune system can attack.

Natural killer cells have long been considered attractive candidates for such strategies. Unlike cytotoxic T lymphocytes, which require recognition of specific tumor antigens presented through the major histocompatibility complex, natural killer cells operate through a system of activating and inhibitory receptors that allow them to detect cells displaying stress ligands or lacking normal self-markers. This makes them capable of killing tumor cells that have downregulated antigen presentation, a common escape route from T cell-based immunotherapy. However, solid tumors, including hepatocellular carcinoma, often present a paucity of the very ligands that activate natural killer cells, blunting the effectiveness of adoptive natural killer cell transfer. The Korean team hypothesized that radiation might solve this problem by forcing tumor cells to display more of these recognition signals.

To test this hypothesis, the researchers worked with three hepatocellular carcinoma cell lines: SNU-398, PLC/PRF/5, and Huh7. Each line was exposed to radiation doses of 5 or 10 Gy, and the cells were then analyzed for changes in immune-related surface markers. The results revealed a consistent but nuanced pattern. Across all three cell lines, radiation increased the expression of several ligands that natural killer cells use to recognize and engage their targets. This radiation-induced upregulation of activating ligands provides a mechanistic rationale for combining radiotherapy with natural killer cell therapy: the irradiated tumor cells effectively become more visible to the innate immune system, presenting more molecular handles for the killer cells to grasp.

The study also uncovered important cell-line-dependent variation that carries significant implications for how such combination therapies might be deployed in the clinic. The magnitude of the ligand increases, the timing of their appearance after irradiation, and the response of PD-L1, the molecule targeted by atezolizumab, all differed among the three cell lines. This heterogeneity means that radiation does not produce a uniform immunological effect across liver cancers; instead, the phenotypic consequences of irradiation depend on the biology of the specific tumor. For clinicians and trial designers, this finding underscores the importance of understanding tumor-specific responses to radiation before assuming that a radiation-priming strategy will work universally.

The functional consequences of these phenotypic changes were most striking in the SNU-398 cell line. When SNU-398 cells were irradiated and then pretreated with the atezolizumab and bevacizumab combination, natural killer cell-mediated lysis increased substantially compared with both nonirradiated cells and cells exposed to the antibody combination alone. In other words, the three modalities did not merely add together; they interacted synergistically. Radiation made the tumor cells more recognizable, the antibodies neutralized inhibitory pathways and modified the tumor-supporting vasculature, and the natural killer cells delivered the lethal blow. This three-way cooperation forms the conceptual core of the study and suggests a rational multimodal framework for treating tumors that have learned to hide from the immune system.

To determine whether these in vitro findings would translate to living tumors, the researchers conducted two separate xenograft experiments using SNU-398 cells implanted in animal models. The design of these experiments proved critical to interpreting the results. In the first model, tumors were allowed to become established and reach an advanced stage before treatment began, mimicking the clinical reality of bulky, progressed disease. In this advanced-stage setting, the full triple combination of irradiation, natural killer cells, and atezolizumab plus bevacizumab produced the greatest tumor growth inhibition among all the tested groups, and it clearly outperformed the natural killer cell plus antibody combination without irradiation. Radiation, in this context, acted as a potentiating agent that tipped the balance in favor of immune-mediated tumor destruction.

The second xenograft model told a different and equally instructive story. In this low-burden, early-stage model, in which tumors were smaller and less established when treatment was initiated, the combination of natural killer cells with atezolizumab and bevacizumab alone was sufficient to suppress tumor growth, and adding irradiation was not required for efficacy. This stage-dependent result is among the most clinically relevant findings of the study. It suggests that the radiation-priming component of the regimen may be most valuable precisely where the clinical need is greatest: in advanced, established tumors that have built up robust immunosuppressive defenses. Earlier in the disease course, when the tumor burden is lower and the microenvironment less entrenched, the antibody and natural killer cell backbone may retain enough activity on its own.

The implications of this work extend beyond hepatocellular carcinoma. The concept of using radiation to upregulate natural killer cell-activating ligands is applicable in principle to many solid tumors that resist current immunotherapies, and the study provides a template for how such combinations should be evaluated: with careful attention to cell-line heterogeneity, dose selection, timing of irradiation relative to cell therapy, and disease stage. The authors are careful to frame their conclusions within the limits of the tested models, noting that the multimodal combination of radiotherapy, atezolizumab plus bevacizumab, and natural killer cell therapy represents a potential strategy to address tumor immune evasion, with radiation contributing most to efficacy against advanced-stage disease. Translating these findings into human trials will require addressing additional questions, including the optimal radiation dosing and fractionation, the source and expansion of natural killer cells for clinical use, and the safety of combining modalities in patients with compromised liver function.

Nevertheless, the study offers a compelling proof of principle that the sequence and combination of existing treatment modalities can be engineered to overcome immune evasion rather than simply applied in parallel. Radiation, often viewed primarily as a local cytotoxic tool, emerges here as an immunological primer that reprograms the tumor surface. Atezolizumab and bevacizumab, already approved for advanced hepatocellular carcinoma, provide checkpoint relief and vascular normalization. Natural killer cells supply the innate cytotoxic arm that can act independently of T cell pathways. The Korean team’s demonstration that these three elements can be woven into a regimen whose effectiveness depends on disease stage represents a meaningful step toward rationally designed, multimodal immunotherapy for one of the world’s deadliest cancers, and it will be watched closely by researchers working to bring natural killer cell-based treatments from the laboratory into the oncology clinic.

Subject of Research: Combining radiation with natural killer cell therapy and immune checkpoint inhibitors to treat hepatocellular carcinoma

Article Title: Radiation potentiates natural killer cell therapy combined with Atezolizumab and Bevacizumab in SNU-398 hepatocellular carcinoma models

Article References: Park, G.-Y., Son, W.-C., Lee, H.-R., Kang, H. B., Kim, W.-T., Yoon, Y. J., Jeon, W., Hwang, S. Y., Kim, Y., & Park, Y.-S. (2026). Radiation potentiates natural killer cell therapy combined with Atezolizumab and Bevacizumab in SNU-398 hepatocellular carcinoma models. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04545-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04545-2

Keywords: hepatocellular carcinoma, natural killer cells, radiation therapy, atezolizumab, bevacizumab, immune checkpoint inhibitors, cell therapy, tumor microenvironment, PD-L1, xenograft models, liver cancer, cancer immunotherapy

Circulating tumor cells are cancer cells that shed from a primary tumor, survive the hostile currents of the bloodstream and can eventually seed new metastases. Because they can be captured from a simple blood draw, they have long been considered one of the most promising liquid biopsy biomarkers in oncology. In hepatocellular carcinoma, where tumors often arise in livers damaged by hepatitis B, hepatitis C or other chronic disease and where tissue biopsies can be risky, a blood test that reliably tracks tumor burden would be transformative. But circulating tumor cells are vanishingly rare, often fewer than a handful per milliliter of blood amid billions of ordinary blood cells, and detecting them demands both extreme enrichment and extremely sensitive identification.

The Fukui team’s workflow began with CD45 depletion–based enrichment, a technique that removes the white blood cells marked by the CD45 surface protein and leaves behind a concentrate enriched for rare non-immune cells, including tumor cells. Both platforms then interrogated this enriched fraction using a common immunophenotypic definition: a cell was counted as a circulating tumor cell if it carried DAPI nuclear staining, indicating intact DNA within a nucleus; lacked CD45, confirming it was not a leukocyte; and expressed pan-cytokeratin, an epithelial marker that liver cancer cells retain even after they leave the tumor. The requirement of preserved nuclear morphology added an important quality gate, filtering out dying cells and debris that might otherwise inflate counts.

FACS, the workhorse of modern cell analysis, pushes thousands of cells per second through a laser interrogation point, measuring fluorescence on multiple channels simultaneously. Its strengths are throughput, multiparametric precision and the ability to quantify absolute cell numbers with statistical rigor. Its weakness is blindness: it reduces each cell to a vector of intensity values, discarding the spatial and structural information that pathologists have relied on for more than a century. TruAI, an image analysis platform built on deep learning, approaches the same enriched sample from the opposite direction. It scans fields of view under a fluorescence microscope and a trained neural network classifies candidate cells, weighing nuclear shape, staining patterns and cytokeratin architecture in a way that mimics, and in principle exceeds, human visual inspection.

To validate that both platforms could actually recover known numbers of tumor cells, the researchers performed spike-in experiments, mixing defined quantities of cultured hepatocellular carcinoma cell lines into blood samples before enrichment. Both methods returned counts that tracked the spiked concentrations with strong linearity, with coefficients of determination exceeding 0.94, meaning that more than 94 percent of the variance in measured counts was explained by the true number of cells present. Notably, FACS consistently registered higher absolute counts than TruAI across the dilution series, a discrepancy the authors interpret in light of the platforms’ different gating strategies and sensitivity thresholds, and one that underscores why head-to-head calibration matters when technologies are used interchangeably in clinical studies.

The clinical core of the study involved 17 patients with hepatocellular carcinoma whose peripheral blood was sampled and analyzed on both platforms. When the counts were compared, the concordance was unmistakable: TruAI-derived and FACS-derived circulating tumor cell counts correlated significantly, with a Pearson correlation coefficient of 0.8216 and an R-squared of 0.675, significant at p below 0.0001. In practical terms, when a patient’s blood registered high on one platform, it registered high on the other, and when treatment drove counts down on one, the other followed. This is precisely the kind of analytic agreement that regulatory scientists look for when deciding whether two assays measure the same biological quantity, and it suggests that either platform could serve as a quantitative readout of circulating tumor burden.

But the study did not stop at static counting. Several of the patients were receiving systemic therapy, including the atezolizumab plus bevacizumab combination that has become the standard first-line regimen for advanced hepatocellular carcinoma, and the team tracked their circulating tumor cells longitudinally across treatment. Both platforms captured the same direction of change, documenting significant decreases in circulating tumor cell numbers as therapy took hold. The convergence of two independently derived measurements on the same biological trend strengthens confidence that the decline was real rather than a processing artifact, and it demonstrates that serial blood-based monitoring is technically feasible with either approach.

The decisive advantage, however, belonged to TruAI, and it was morphological. Because the imaging platform retains the architecture of each detected cell, the researchers could distinguish solitary circulating tumor cells from circulating tumor cell clusters, small aggregates of two or more tumor cells traveling together. Clusters are widely regarded as the more dangerous currency of metastasis; experimental work across multiple tumor types has shown that cell clusters seed metastases far more efficiently than single cells, and cluster burden has been associated with worse prognosis. In the Fukui cohort, the proportion of circulating tumor cells found in clusters fell in patients who achieved disease control, and those reductions in cluster proportion ran in parallel with radiologically confirmed tumor shrinkage and with declining levels of serum tumor markers, including alpha-fetoprotein and des-gamma-carboxy prothrombin, the two canonical biomarkers of hepatocellular carcinoma activity.

That parallelism is the quiet headline of the study. A blood test that reports not just how many tumor cells are circulating but how they are organized, and that tracks those organizational changes in step with what radiologists see on CT and MRI, moves the liquid biopsy closer to functioning as a genuine surrogate of treatment response. For patients with hepatocellular carcinoma, where response assessment currently depends on imaging performed at fixed intervals and where serum markers can be insensitive in a substantial fraction of cases, a morphologically informative blood assay could eventually allow earlier detection of treatment failure and faster escalation to second-line options. The authors are careful about scope: their conclusions position the combined use of TruAI imaging and flow cytometry as a way to enhance longitudinal monitoring by capturing both total circulating tumor cell burden and cluster dynamics, not as a validated diagnostic or prognostic test ready for routine deployment.

The study’s limitations are those of an early-phase evaluation: a small cohort of 17 paired clinical samples, a single institution, and a sensitivity analysis using all 31 paired samples reported in supplementary material rather than a multicenter validation. Yet the technical message is already clear and, in a field crowded with competing liquid biopsy platforms, unusually constructive. Counting and seeing are not rival philosophies but complementary layers of the same measurement. Flow cytometry supplies speed, absolute quantification and multiparametric depth; AI-driven imaging supplies structure, morphology and the ability to recognize biologically meaningful subpopulations such as clusters that a flow cytometer sweeps past without notice. As deep learning image analysis matures and regulatory pathways for AI-based diagnostics take shape, the Fukui results argue that the most powerful blood test for liver cancer may be the one that learns to do both at once.

Subject of Research: AI-assisted imaging and flow cytometry for circulating tumor cell detection in hepatocellular carcinoma

Article Title: Parallel Evaluation of TruAI-assisted imaging and flow cytometry for circulating tumor cell detection in hepatocellular carcinoma

Article References: Lyu, J., Nosaka, T., Nomiya, H., Murata, Y., Akazawa, Y., Tanaka, T., Takahashi, K., Naito, T., Ohtani, M., Zhang, L., & Nakamoto, Y. (2026). Parallel Evaluation of TruAI-assisted imaging and flow cytometry for circulating tumor cell detection in hepatocellular carcinoma. BMC Cancer. https://doi.org/10.1186/s12885-026-17005-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17005-y

Keywords: hepatocellular carcinoma, circulating tumor cells, liquid biopsy, TruAI, flow cytometry, artificial intelligence, deep learning, CTC clusters, atezolizumab, bevacizumab, biomarkers, BMC Cancer

The TKI era delivered incremental but real gains. Lenvatinib emerged as a non-inferior first-line alternative to sorafenib, while regorafenib, cabozantinib, and the anti-VEGFR-2 antibody ramucirumab — the latter reserved for patients with alpha-fetoprotein levels of at least 400 ng/mL — extended survival after sorafenib failure. Yet the ceiling was low: median life expectancy on first-line TKI therapy rarely exceeded 12 to 13 months. Progressive liver dysfunction, clinical decompensation, and the difficulty of tolerating TKIs long-term exposed a fundamental limitation. Immune checkpoint inhibitors (ICIs) tested as monotherapy also failed to beat sorafenib in phase III studies, leaving the field at an impasse until combination immunotherapy arrived.

The turning point came with regimens that pair PD-1 pathway blockade with either VEGF inhibition or CTLA-4 inhibition. Median overall survival for untreated advanced HCC patients, once roughly six months, climbed to between 16 and 23 months in contemporary phase III trials — a leap accompanied by higher response rates, better safety profiles, and improved quality of life. Four pivotal trials now define first-line care. IMbrave150 showed atezolizumab plus bevacizumab (A + B) achieved a median overall survival of 19.2 months versus 13.4 months for sorafenib, with an objective response rate of 30% versus 11%, though six grade 5 bleeding events in the combination arm underscored the need for baseline endoscopic varices screening. HIMALAYA demonstrated that a single priming dose of tremelimumab plus monthly durvalumab (the STRIDE regimen) improved median survival to 16.4 months, with striking five-year survival of 19.6% compared with 9.4% for sorafenib.

CheckMate 9DW added a third option, combining ipilimumab induction with nivolumab maintenance against a control arm dominated by lenvatinib. Median overall survival reached 23.7 months versus 20.6 months, with a 36% response rate and a 48-month survival rate of 31% versus 18%. Notably, early deaths from hepatic events caused the survival curves to cross within the first six months, a reminder that close monitoring for liver decompensation is essential. The fourth positive trial, CARES-310, paired camrelizumab with the TKI rivoceranib and achieved the highest hazard ratio benefit (0.64) and a 23.8-month median survival — but with grade 3–4 toxicity in 81% of patients and a predominantly Asian, hepatitis B-driven population, its results are difficult to extrapolate to Europe, where alcohol-related liver disease, hepatitis C, and metabolic dysfunction-associated steatohepatitis (MASH) predominate.

Underlying liver disease aetiology was once thought to blunt immunotherapy efficacy, particularly in MASH-related HCC, but subsequent analyses have been inconsistent, and current European Society for Medical Oncology (ESMO) guidelines recommend the approved regimens regardless of aetiology. A thornier question concerns patients with Child-Pugh B liver dysfunction, who were largely excluded from phase III trials. Evidence from CheckMate 040 cohort 5 — where nivolumab achieved a 12% response rate and 7.6-month median survival in 49 Child-Pugh B7–B8 patients — and from a meta-analysis of 22 studies suggests immunotherapy is not absolutely contraindicated, though survival is markedly worse than in patients with preserved liver function. The authors stress that the cause of hepatic decline, whether tumour burden or decompensated cirrhosis, must be weighed case by case, ideally with refined tools such as the ALBI grade and within multidisciplinary team consensus.

Managing immune-related liver injury has itself become a core clinical skill. Because HCC arises on a backdrop of chronic liver disease, immune-mediated hepatotoxicity occurs earlier and more frequently than in other solid tumours, and diagnosis is complicated by the absence of specific criteria and by baseline liver test abnormalities. Most cases resolve without permanent discontinuation, but fatal hepatic toxicities have been reported, making vigilant monitoring and early multidisciplinary involvement non-negotiable elements of modern care.

What happens after first-line immunotherapy fails remains one of the field’s largest unmet needs. ESMO guidelines recommend only TKIs — sorafenib, lenvatinib, regorafenib, or cabozantinib — or ramucirumab in the second line, regardless of prior immunotherapy exposure. Observational data from the European LEVIATHAN registry favour lenvatinib over sorafenib after A + B failure (progression-free survival of 5.5 versus 2.6 months), and single-arm Asian phase II trials support regorafenib and cabozantinib in this setting. The recent IMbrave251 trial, though negative for its primary endpoint, provided the first randomised phase III benchmark for TKI monotherapy after first-line immunotherapy: 12.5-month overall survival and 4.8-month progression-free survival in the TKI-only arm. Crucially, no immunotherapy agent holds European approval in the second line — a stark contrast with the United States, where pembrolizumab and ipilimumab plus nivolumab are licensed after TKI failure. Off-label immunotherapy use in Europe therefore depends on institutional policies and is often not reimbursed, pushing costs onto hospital budgets, insurers, or patients themselves.

Access inequity emerges as the review’s most provocative theme. Although the European Medicines Agency grants EU-wide marketing authorisation, national reimbursement decisions vary enormously. Atezolizumab plus bevacizumab and the STRIDE regimen are now reimbursed in 23 and 18 European countries respectively, but ipilimumab plus nivolumab — EMA-approved in March 2025 — was, more than a year later, reimbursed in only one country, Germany. During 2016–2021, compliance with the EU’s recommended 180-day reimbursement deadline ranged from 100% in Germany to just 3% in Belgium. Molecular profiling offers little help in personalising choices: no genomic alteration in HCC reaches the top tiers of the ESMO ESCAT framework, and in the French Genomic Programme only 3 of 135 HCC patients were successfully matched to a targeted therapy. Emerging predictors — tumour immune contexture signatures, the CRAFITY score combining AFP and C-reactive protein, radiomic machine-learning models, and gut microbiome profiles — show promise but await prospective validation.

Meanwhile, European practice is quietly diverging from guidelines in the locoregional arena. Trans-arterial chemoembolization remains the standard for liver-confined intermediate-stage disease, and phase II/III trials including EMERALD-1 and LEAP-012 have shown progression-free survival gains from adding PD-1/PD-L1 blockade to TACE — though no overall survival benefit has yet been demonstrated and no European marketing authorisation exists for the combination. Selective internal radiotherapy (SIRT) with yttrium-90 microspheres, once dismissed after the negative SARAH and SIRveNIB trials, has been rehabilitated by the DOSISPHERE-01 study, which showed that personalised dosimetry delivering at least 205 Gy to the tumour significantly improves survival, even in patients with portal vein thrombosis. The prospective French PROACTIF registry of 989 patients reported 21.8-month median survival after SIRT, yet no randomised comparison with immunotherapy exists, leaving a widening gap between routine practice and guideline-endorsed standards.

The authors call for a coordinated, multi-stakeholder response: harmonised reimbursement pathways, prospective evidence for treatment sequencing, validated predictive biomarkers, broader access to clinical trials beyond academic centres through platforms such as the EU’s Clinical Trials Information System, and universal multidisciplinary review — potentially expanded through virtual networks supported by artificial intelligence. With HCC ranking thirteenth by incidence and sixth by mortality in Europe, the science has finally delivered survival gains once thought impossible. The remaining challenge, the review concludes, is no longer inventing effective treatments but ensuring that every European patient can actually receive them.

Subject of Research: Systemic and locoregional treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe

Article Title: Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe

Article References: Pinato, D. J., Alimenti, E., Lombardi, P., Vaz, J., Digklia, A., Edeline, J., Ben Khaled, N., Di Giacomo, E., Scheiner, B., Ramos, J. P., O’Kane, G. M., Cappuyns, S., Tesini, G., & Rimassa, L. (2026). Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe. The Lancet Regional Health – Europe, 70, Article 101839. https://doi.org/10.1016/j.lanepe.2026.101839

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101839

Keywords: hepatocellular carcinoma, immunotherapy, atezolizumab, bevacizumab, durvalumab, tremelimumab, tyrosine kinase inhibitors, EMA, reimbursement, health inequality, locoregional therapy, biomarkers

The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, was motivated by a stubborn clinical problem. Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis have transformed the treatment of melanoma and lung cancer, producing durable responses and long-term survival in subsets of patients. Prostate cancer, however, has largely resisted this revolution. Only small fractions of men with mCRPC benefit from agents such as pembrolizumab or nivolumab, a failure attributed to the disease’s low tumor mutational burden and its profoundly immunosuppressive microenvironment. Prostate tumors are, in immunological terms, cold: they present few recognizable targets to T cells and actively suppress the immune cells that do infiltrate them.

Radiation has long been proposed as a way to heat those cold tumors up. External beam radiotherapy can damage cancer cells in ways that release tumor antigens, trigger inflammatory cytokine secretion, recruit dendritic cells, and activate anti-tumor T cells. In rare, striking cases, irradiating one tumor site has even shrunk untreated lesions elsewhere in the body, the so-called abscopal effect. Clinical trials combining radiation with checkpoint inhibitors have shown hints of enhanced activity in genitourinary cancers. Radium-223, an intravenously administered alpha emitter approved for mCRPC patients with predominantly bone metastases, seemed like an elegant systemic version of this strategy. In the pivotal phase III ALSYMPCA trial it extended overall survival by 3.6 months, and because it circulates through the bloodstream it can in principle irradiate every bone lesion at once.

Earlier laboratory work had fed optimism. In vitro experiments showed that sublethal exposure to radium-223 enhanced the ability of cytotoxic T lymphocytes to kill prostate cancer cells by inducing MHC class I and calreticulin, proteins central to antigen presentation. Studies of patient blood revealed that radium-223 enriched DNA damage repair pathways in plasma exosomes and raised exosomal levels of PD-L1, LAG-3 and IDO, immune checkpoints associated with immunosuppression and poorer survival. A mouse model of prostate cancer even suggested that combining radium-223 with anti-PD-1 and anti-CTLA-4 antibodies produced greater tumor regression than either immunotherapy alone. The clinical rationale for combining the radionuclide with checkpoint blockade appeared, on the surface, compelling.

To test that rationale rigorously in humans, the research team designed a biomarker discovery study in which patients received up to six injections of radium-223 at four-week intervals, while undergoing an unusually demanding battery of measurements. The centerpiece was sequential PET imaging with zirconium-89 labeled atezolizumab, a radiolabeled version of the approved PD-L1 antibody atezolizumab. Produced under Good Manufacturing Practice at the University Medical Center Groningen and injected at a tracer dose of 37 MBq, roughly 11 milligrams of antibody and less than one percent of a therapeutic dose, the tracer allowed the team to quantify whole-body PD-L1 expression in vivo, something a single biopsy can never do. Gallium-68 PSMA PET/CT served as the anatomical and molecular reference, pinpointing viable prostate cancer lesions in the skeleton against which atezolizumab uptake could be measured.

The imaging results were striking. At baseline, uptake of the PD-L1 tracer in PSMA-positive bone metastases was low overall and highly heterogeneous, both between patients and between individual lesions within the same patient, with a median standardized uptake value of 2.5 across the total volume of PSMA-positive bone disease. After three cycles of radium-223, that median fell to 0.9, a statistically significant median decrease of 33 percent, while PSMA uptake in the same lesions remained essentially stable. Crucially, the decline was independent of whether a patient’s disease responded on PSMA PET: good responders, defined as those remaining on radium-223 for at least 24 weeks, and poor responders showed comparable drops. Some lesions even lost PD-L1 signal while their PSMA signal held steady, and new PSMA-avid disease appearing at the borders of treated lesions showed lower tracer uptake than the original metastases had at baseline.

Tissue analysis told a consistent story. Guided by PSMA PET, the team obtained bone metastasis biopsies at baseline in 25 patients, with tumor cells present in 76 percent of samples. Multiplex immunohistochemistry revealed low PD-L1 expression, found mainly on tumor cells but also on non-tumor cells, mirroring the modest and variable PET signal. In the small number of patients who provided sequential biopsies, the number of lymphocytes in both tumor tissue and surrounding bone marrow decreased after three cycles of radium-223, and one on-treatment biopsy showed necrosis consistent with radiation effect. Flow cytometry of blood samples reinforced the picture: circulating lymphocyte counts fell during therapy, and good responders showed a significant rise in TIM3-positive T cells, a marker of T cell exhaustion, after treatment.

The authors argue that the drop in atezolizumab uptake most likely reflects a treatment-induced loss of immune cells within the tumor microenvironment, and possibly a reduction in PD-L1 expression per cell, rather than simply fewer tumor cells. Because PSMA uptake did not fall in parallel, and because new PSMA-positive disease did not carry elevated PD-L1 signal, the immune compartment appears to be the dominant source of the tracer signal and the main casualty of the alpha radiation. The team acknowledges limitations, including the possibility of confounding by changes in tumor vascularization or receptor saturation, though the stability of tracer uptake in bone marrow and cortex over time supports a genuine treatment effect. Sequential biopsies were feasible in only a handful of patients, and decalcification of bone samples may have masked PD-L1 staining with standard clinical antibodies.

The clinical implications are sobering but clarifying. The findings align with the disappointing results of phase Ib and phase II trials that added radium-223 to atezolizumab, pembrolizumab or enzalutamide and found no benefit for mCRPC patients. Far from sensitizing prostate cancer to PD-L1 blockade, alpha radiation appears to thin out the very immune cells that checkpoint inhibitors rely upon, potentially undermining immunogenic effects of irradiation through sheer depletion of the lymphocyte pool. The researchers suggest that future combination strategies might instead turn to radionuclides with lower linear energy transfer delivered at lower doses, such as lutetium-177 PSMA-targeted therapy, which could induce immunogenic signaling without devastating the immune infiltrate. For now, the study stands as a powerful demonstration of what whole-body immune PET can reveal: a molecular narrative of treatment response that biopsies alone could never tell, and a cautionary lesson about assuming that radiation and immunotherapy are natural allies in every tumor type.

Subject of Research: The effect of radium-223 alpha radiation on PD-L1 expression and the immune microenvironment of bone metastases in metastatic castration-resistant prostate cancer, measured with zirconium-89 atezolizumab PET imaging and immunohistochemistry.

Article Title: Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation

Article References: Ling, S. W., de Jong, A., Gorris, M., Segbers, M., Graven, L., van Driel, M., van Leenders, G., Isebia, K., de Hooge, M. L., Hamberg, P., Mehra, N., van Brakel, M., de Wit, R., Debets, R., de Vries, E., Brabander, T., de Vries, J., & van der Veldt, A. (2026). Radium-223 decreases PD-L1 expression in bone metastases: A study with [89Zr]Zr-atezolizumab PET and immunohistological correlation. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08175-9

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08175-9

Keywords: radium-223, prostate cancer, PD-L1, atezolizumab, PET imaging, bone metastases, immune checkpoint inhibitors, PSMA, immunotherapy, alpha radiation, tumor microenvironment, mCRPC

The IMpower030 trial was designed to test whether adding an immune checkpoint inhibitor to the standard surgical pathway could reshape the natural history of a cancer that is often caught at an operable stage but still returns in a large fraction of patients. In the experimental arm, patients received atezolizumab combined with platinum-based chemotherapy before surgery, a strategy known as neoadjuvant therapy, and then continued atezolizumab after surgery as adjuvant treatment. Patients in the comparator arm received the same chemotherapy backbone with placebo in place of the immunotherapy drug. This perioperative design is intended to attack the tumor while it is still in the body, priming the immune system against cancer cells before the primary tumor is removed, and then sustaining that immune pressure afterward to eliminate microscopic disease that surgery alone cannot reach.

The headline result, a median event-free survival of 62.8 months versus 34.9 months, means that half of the patients in the atezolizumab arm had not experienced an event such as disease recurrence, progression, or death by more than five years after starting treatment, while the corresponding milestone in the chemotherapy-only arm arrived almost two years earlier. For a disease that historically carried a high risk of relapse even after complete surgical resection, the magnitude of the separation between the two curves offers a striking illustration of how immunotherapy has changed the treatment landscape. Event-free survival is a particularly meaningful endpoint in the perioperative setting because it captures the full impact of both pre- and post-surgical therapy on keeping the disease at bay.

Beyond the survival data, the trial demonstrated substantially higher rates of pathological response in tumors removed at surgery. Pathological complete response, meaning that no viable cancer cells could be identified in the resected specimen, was achieved in 29.6 percent of patients treated with atezolizumab plus chemotherapy compared with 8.5 percent of those receiving chemotherapy alone. Major pathological response, a measure of residual viable tumor of 10 percent or less, was seen in 53.6 percent versus 24.4 percent of patients respectively. These pathological endpoints matter because they reflect what actually happened inside the tumor under the pressure of treatment, and a deep pathological response before surgery is widely regarded as one of the strongest early indicators of long-term benefit in lung cancer and several other tumor types.

Pathological response and event-free survival are connected by biology. When immunotherapy recruits the body’s own T cells to recognize and destroy cancer cells, tumors that respond often shrink dramatically or are replaced largely by immune infiltrates and fibrous tissue. Removing a tumor that has already been largely eradicated by the immune system leaves behind fewer viable cells capable of seeding recurrence. The IMpower030 data are consistent with that model: the arm with nearly twice the rate of major pathological response also showed the longer event-free survival, reinforcing the idea that the depth of response achieved before surgery translates into durable clinical benefit over the years that follow.

An important nuance in the trial’s interpretation is that it did not meet its predefined threshold for statistical significance. In clinical research, a trial is typically designed with a specific statistical bar that must be crossed for the result to be declared formally positive, and IMpower030 fell short of that bar. Nevertheless, the investigators reported clinically meaningful improvements across multiple efficacy endpoints, including event-free survival as assessed by an independent review facility, event-free survival as assessed by the treating investigators, disease-free survival, and overall survival. The consistency of the benefit across independently and investigator-assessed measures, and across endpoints that capture both recurrence and death, strengthens confidence that the observed advantage reflects a real treatment effect rather than a statistical artifact.

Safety and surgical feasibility were also central questions for a perioperative strategy, because any therapy given before surgery must not compromise the ability to perform a potentially curative operation. In IMpower030, surgical cancellation rates remained low and were similar between the two treatment groups, indicating that preoperative atezolizumab did not prevent patients from proceeding to their operations. No new safety signals were identified, meaning that the side-effect profile observed in this final analysis was consistent with what is already known about atezolizumab and platinum-based chemotherapy. The investigators did note that adverse events occurred more frequently during the neoadjuvant phase than during the adjuvant phase in both treatment arms, a pattern consistent with the combined intensity of chemotherapy and immunotherapy delivered before surgery and with the general tendency of treatment-related toxicity to cluster early in a treatment course.

Benjamin Solomon, M.D., of the Peter MacCallum Cancer Centre in Melbourne, Australia, the presenting author of the results, said that the long-term findings demonstrate clinically meaningful improvements across several important outcomes and further support the role of perioperative immunotherapy for patients with resectable non-small cell lung cancer. His assessment captures the position the trial now occupies in the field: while the formal statistical threshold was not met, the breadth and durability of the improvements across endpoints, together with the strong pathological response rates and the absence of new safety concerns, provide substantial support for the perioperative approach in this patient population.

The significance of these results extends beyond a single trial. Non-small cell lung cancer remains the leading cause of cancer death worldwide, and even among patients whose disease is caught early enough for surgery, relapse rates have historically been discouragingly high. The addition of immune checkpoint inhibitors to perioperative treatment represents a fundamental shift from a strategy built almost entirely on the surgeon’s scalpel to one that enlists the immune system as an active partner in eradicating the disease. Long-term data such as those from IMpower030 are essential for understanding whether that shift produces lasting cures rather than merely delayed recurrences, and the five-year median event-free survival reported here suggests that a meaningful proportion of patients may be experiencing durable control of their disease.

For clinicians managing resectable stage II to IIIB non-small cell lung cancer, the final IMpower030 results add weight to the growing body of evidence supporting perioperative immunotherapy as a standard component of care. The trial’s findings on pathological response give treating physicians an early and measurable signal of benefit, while the event-free survival and overall survival data provide the longer-term reassurance that early responses translate into extended periods without disease recurrence. As the lung cancer community continues to refine which patients benefit most from perioperative immunotherapy, how long adjuvant treatment should continue, and how best to sequence systemic therapy with surgery, the IMpower030 trial stands as a landmark demonstration that combining atezolizumab with platinum-based chemotherapy before and after surgery can more than double the time patients live free of cancer-related events, reshaping expectations for one of the most common and lethal malignancies in the world.

Subject of Research: Perioperative atezolizumab plus chemotherapy for resectable stage II–IIIB non-small cell lung cancer in the Phase 3 IMpower030 trial

Article Title: Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC

Article References: Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: non-small cell lung cancer, atezolizumab, IMpower030, perioperative immunotherapy, event-free survival, pathological complete response, platinum-based chemotherapy, neoadjuvant therapy, adjuvant therapy, resectable lung cancer, immune checkpoint inhibitor, IASLC World Conference on Lung Cancer

The central concept behind the research is receptor saturation. Atezolizumab is a monoclonal antibody designed to bind PD-L1, a protein that many tumours deploy on their surfaces to suppress the immune cells that would otherwise attack them. By occupying PD-L1, atezolizumab blocks this molecular camouflage and releases the brakes on the immune system. But the drug can only work where it actually reaches the target in sufficient quantity. If a tumour expresses abundant PD-L1 but has poor blood supply, dense stromal barriers, or unfavourable pharmacokinetics, the antibody may fail to saturate the target even though the patient receives a full therapeutic dose. Conventional testing, which involves staining a biopsy sample for PD-L1 expression, captures only a snapshot of a tiny fragment of the tumour at a single moment in time and says nothing about whether the drug is engaging its target throughout the body.

PET imaging offers a fundamentally different perspective. In the approach examined by the researchers, atezolizumab is labelled with a radioactive tracer, typically the radionuclide zirconium-89, whose decay signature can be detected by the PET scanner. When the labelled antibody is injected into a patient, the scanner produces three-dimensional maps showing exactly where the drug accumulates. If a tumour lights up with signal before treatment, it indicates that PD-L1 is present and accessible to the antibody. If the signal diminishes or disappears after the patient begins therapy with unlabelled atezolizumab, it indicates that the therapeutic antibody has flooded the target sites, occupying them so thoroughly that the labelled tracer can no longer bind. This drop in tracer uptake is the imaging signature of target saturation, the pharmacodynamic state in which the drug is doing its intended molecular job at the tumour site.

The logic of this imaging paradigm rests on a simple competitive principle. Before treatment begins, when no therapeutic antibody is circulating, the radiolabelled atezolizumab analogue can bind freely to PD-L1 molecules on tumour cells, producing strong PET signal. Once a patient starts standard atezolizumab infusions, the circulating therapeutic antibody competes with the tracer for the same binding sites. As the drug concentration rises and saturates available PD-L1, tracer uptake falls. The degree of that fall provides a direct, whole-body measure of how completely the treatment is engaging its target in each tumour lesion. This is often described as an in vivo pharmacodynamic biopsy: instead of sampling one lesion surgically, clinicians can observe drug-target interactions across every detectable tumour deposit simultaneously, including metastases in locations that could never be biopsied safely.

The significance of this capability becomes clear when considering how immunotherapy is currently managed. Patients with non-small cell lung cancer, bladder cancer, and other PD-L1-positive malignancies typically receive atezolizumab or similar agents on fixed schedules, often for months, before standard imaging can reveal whether the tumours are shrinking. Response assessment by CT generally takes weeks to months to show meaningful change, because tumour shrinkage is a delayed downstream consequence of immune activation. Target saturation, by contrast, is an immediate upstream event. If imaging shows that the antibody has fully occupied PD-L1 within days of the first dose, and the tumour still fails to respond over the following months, the problem lies elsewhere: the tumour may have developed alternative immune-evasion mechanisms, the tumour microenvironment may lack infiltrating T cells, or downstream signalling may be blocked. Distinguishing pharmacokinetic failure, where the drug never reached the target, from biological resistance, where the drug engaged the target but the cancer resisted anyway, is exactly the information that saturation imaging is designed to provide.

Past work in this field has demonstrated the technical feasibility of the approach. Radiolabelled versions of atezolizumab and the related antibody pembrolizumab have been used in early-phase clinical trials, showing that PD-L1-specific PET signal can be detected in human tumours, that uptake varies widely between patients, and that heterogeneity exists even among different metastatic lesions within the same individual. These studies revealed something that biopsies had long obscured: a patient whose primary tumour shows strong PD-L1 staining may harbour liver metastases with negligible target expression, and those lesions may behave very differently under treatment. Quantitative measures derived from PET scans, such as standardised uptake values, have been correlated with clinical outcomes in preliminary analyses, hinting that baseline tracer uptake and early changes during therapy could serve as predictive biomarkers in their own right.

Dosing is another area where saturation imaging carries substantial implications. Current atezolizumab regimens were established through trials that sought doses safely exceeding the levels needed for receptor occupancy, but those occupancy estimates were largely derived from circulating drug levels and receptor occupancy measurements on peripheral blood cells, not from direct measurements inside tumours. Tumour penetration is governed by different physics: antibody extravasation through leaky but uneven vasculature, diffusion through the extracellular matrix, binding-site barriers created by dense target expression near blood vessels, and clearance rates that vary with tumour type and location. PET saturation imaging brings these hidden variables into view. A tumour that retains strong tracer uptake even after multiple treatment doses is telling clinicians that the target remains unsaturated, suggesting that dose escalation, altered scheduling, or combination strategies that improve drug delivery might be worth considering for that specific patient.

The study published in the British Journal of Cancer contributes to this evolving evidence base by evaluating PD-L1 PET/CT specifically as a tool to assess tumour saturation during atezolizumab treatment. The broader research programme of which it forms a part reflects a decisive shift in oncology drug development: away from one-size-fits-all dosing and toward imaging-verified pharmacodynamics. Regulatory science has begun to take note. Methods that demonstrate target engagement early in treatment could accelerate clinical trials by providing early surrogate indicators, reducing the sample sizes and follow-up durations needed to establish whether a drug regimen is mechanistically active. They could also support adaptive treatment strategies in routine care, in which imaging results after the first one or two doses inform whether the patient should continue, switch, or intensify therapy long before tumour volume changes would be visible.

Challenges remain before such imaging can enter routine practice. Radiolabelling antibodies with zirconium-89 requires cyclotron facilities, radiochemistry expertise, and regulatory compliance that currently limits availability to specialised centres. The half-life of zirconium-89, roughly 78 hours, suits the slow pharmacokinetics of antibodies, which circulate for days to weeks before reaching peak tumour uptake, but it also means patients must return for scans several days after injection and absorb a meaningful radiation dose. Cost, reimbursement, and the need for standardised scanning protocols and uptake thresholds all stand between promising trial results and clinical adoption. Questions also persist about how best to interpret partial saturation, how tracer signal in the liver and spleen, organs with high background antibody uptake, affects quantification of abdominal lesions, and how the immune response triggered by treatment itself alters target expression over time.

Nevertheless, the trajectory of the field is unmistakable. Molecular imaging of drug-target engagement is converging with immunotherapy at a moment when the limitations of current biomarkers have become painfully evident. PD-L1 immunohistochemistry, tumour mutational burden, and gene-expression signatures each capture only a fragment of the biology that determines whether a patient responds to checkpoint blockade. Saturation imaging promises something those tools cannot: a dynamic, whole-body, patient-specific readout of whether the drug is doing, at the molecular level, what it was designed to do. If validated in larger cohorts, the approach exemplified by this line of research could move immunotherapy closer to the ideal of precision medicine, where the first weeks of treatment generate actionable information rather than a waiting period measured in months. For the many patients whose tumours do not respond to atezolizumab and its peers, that shift could mean less time on ineffective therapy, faster transitions to alternatives, and a clearer mechanistic understanding of why immunotherapy succeeds or fails in each individual.

Subject of Research: PD-L1 PET/CT molecular imaging to assess tumour target saturation during atezolizumab immunotherapy

Article Title: Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment

Article References: Hooiveld-Noeken, J. S., van de Donk, P. P., Kist de Ruijter, L., Kok, I. C., van Winkel, C. A. J., Giesen, D., Lub-de Hooge, M. N., Brouwers, A. H., Oosting, S. F., Bensch, F., Smit, L. M., Schröder, C. P., Jalving, M., Elias, S. G., Gietema, J. A., Deurloo, R. J., Williams, S. P., Ungewickell, A., de Groot, D.-J. A., & de Vries, E. G. E. (2026). Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03595-8

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03595-8

Keywords: PD-L1, PET/CT imaging, atezolizumab, immunotherapy, checkpoint inhibitors, target saturation, molecular imaging, radiotracer, tumour microenvironment, pharmacodynamics, precision oncology, British Journal of Cancer